Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
CC transcript
|
|
Molecular Insight Pharmaceuticals, Inc. (MIPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/13/2011 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)] |
| 05/11/2011 |
8-K
| Quarterly results |
| 05/05/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 05/05/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 05/04/2011 |
8-K
| Form 8-K - Current report |
| 04/20/2011 |
SC 13G/A
| Savitr Capital, LLC reports a 1.1% stake in MOLECULAR INSIGHT PHARMACERUTICALS, INC. |
| 04/20/2011 |
8-K
| Form 8-K - Current report |
| 03/28/2011 |
SC 13G/A
| Savitr Capital, LLC reports a 10.8% stake in MOLECULAR INSIGHT PHARMACERUTICALS, INC. |
| 03/16/2011 |
8-K
| Form 8-K - Current report |
| 03/10/2011 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/09/2011 |
SC 13D/A
| Taconic Capital Advisors LP has filed a Schedule 13D for ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 03/09/2011 |
SC 13D/A
| McDonnell Loan Opportunity Ltd. has filed a Schedule 13D for Schedule 13D WASHINGTON, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 03/09/2011 |
SC 13D/A
| Molecular Insight Pharmaceuticals, Inc. has filed a Schedule 13D for ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 03/09/2011 |
SC 13D/A
| Molecular Insight Pharmaceuticals, Inc. has filed a Schedule 13D for ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 03/08/2011 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...|
Docs:
|
"Plan Support Agreement between Molecular Insight Pharmaceuticals, Inc. and Certain Holders of Bonds, and effective March 1, 2011",
"DIP Commitment Letter between Molecular Insight Pharmaceuticals, Inc. and Certain Holders of Bonds and Their Affiliate Entities, and effective March 1, 2011",
"Exit Commitment Letter between Molecular Insight Pharmaceuticals, Inc. and Certain Holders of Bonds and Their Affiliate Entities, and effective March 1, 2011",
"Molecular Insight Accepts Alternative Transaction Proposal and Files Amended Plan of Reorganization" |
|
| 02/24/2011 |
SC 13D
| Savitr Capital, LLC reports a 10.5% stake in Molecular Insight Pharmaceuticals, Inc. |
| 02/18/2011 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/08/2011 |
8-K
| Form 8-K - Current report |
| 01/26/2011 |
8-K
| Form 8-K - Current report |
| 01/24/2011 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 01/21/2011 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 01/12/2011 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
| 01/12/2011 |
SC 13D/A
| Molecular Insight Pharmaceuticals, Inc. has filed a Schedule 13D for ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 01/12/2011 |
SC 13D/A
| Taconic Capital Advisors LP has filed a Schedule 13D for ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 01/12/2011 |
SC 13D/A
| McDonnell Loan Opportunity Ltd. has filed a Schedule 13D for Schedule 13D Washington, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 01/11/2011 |
SC 13D/A
| Form SC 13D - General statement of acquisition of beneficial ownership [amend] |
| 12/29/2010 |
8-K
| Form 8-K - Current report |
| 12/21/2010 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/14/2010 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Trigg...|
Docs:
|
"Investment Agreement, between Molecular Insight Pharmaceuticals, Inc. and Savitr Capital LLC",
"Severance Agreement, between Molecular Insight Pharmaceuticals, Inc. and Daniel L. Peters, with resignation effective on December 8, 2010",
"Severance Agreement, between Molecular Insight Pharmaceuticals, Inc. and Charles H. Abdalian, Jr., with resignation effective on December 8, 2010",
"Consulting Agreement, between Molecular Insight Pharmaceuticals, Inc. and Harry Stylli",
"Interim Services Agreement between Molecular Insight Pharmaceuticals, Inc. and Tatum, a division of SFN Professional Services LLC",
"Molecular Insight Announces $45-Million Financing Commitment, Chapter 11 Filing, Corporate Restructuring and Management Changes" |
|
| 11/19/2010 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 11/04/2010 |
10-Q
| Quarterly Report for the period ended September 30, 2010 |
| 11/04/2010 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 11/03/2010 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 10/22/2010 |
8-K
| Form 8-K - Current report |
|
|
|